- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease ; volume:9 ; number:1 ; day:31 ; month:8 ; year:2023 ; pages:1-12 ; date:12.2023
npj Parkinson's Disease ; 9, Heft 1 (31.8.2023), 1-12, 12.2023
- Urheber
-
Martinez-Carrasco, Alejandro
Real, Raquel
Lawton, Michael
Iwaki, Hirotaka
Tan, Manuela M. X.
Wu, Lesley
Williams, Nigel M.
Carroll, Camille
Hu, Michele T. M.
Grosset, Donald G.
Hardy, John
Ryten, Mina
Foltynie, Tom
Ben-Shlomo, Yoav
Shoai, Maryam
Morris, Huw R.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41531-023-00573-2
- URN
-
urn:nbn:de:101:1-2024020112211640333962
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:26 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Martinez-Carrasco, Alejandro
- Real, Raquel
- Lawton, Michael
- Iwaki, Hirotaka
- Tan, Manuela M. X.
- Wu, Lesley
- Williams, Nigel M.
- Carroll, Camille
- Hu, Michele T. M.
- Grosset, Donald G.
- Hardy, John
- Ryten, Mina
- Foltynie, Tom
- Ben-Shlomo, Yoav
- Shoai, Maryam
- Morris, Huw R.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease
Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia
Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson’s disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
Predicting levodopa-induced dyskinesia
Multivariable clinical-genetic model for predicting dyskinesia in early-onset Parkinson’s disease
The NONRATT023402.2/rno-miR-3065-5p/NGFR axis affects levodopa-induced dyskinesia in a rat model of Parkinson’s disease
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease
Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia
Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson’s disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
Predicting levodopa-induced dyskinesia
Multivariable clinical-genetic model for predicting dyskinesia in early-onset Parkinson’s disease
The NONRATT023402.2/rno-miR-3065-5p/NGFR axis affects levodopa-induced dyskinesia in a rat model of Parkinson’s disease
Diagnostic prediction model for levodopa-induced dyskinesia in Parkinson’s disease
Mavoglurant (AFQ056) for the treatment of levodopa-induced dyskinesia in patients with Parkinson’s disease: a meta-analysis
24-hour levodopa-carbidopa intestinal gel may reduce troublesome dyskinesia in advanced Parkinson’s disease
Risk factors of levodopa-induced dyskinesia in Parkinson’s disease: results from the PPMI cohort
Low serum uric acid levels and levodopa-induced dyskinesia in Parkinson's disease
Altered perivascular spaces in subcortical white matter in Parkinson’s disease patients with levodopa-induced dyskinesia
Contracted thalamic shape is associated with early development of levodopa-induced dyskinesia in Parkinson’s disease
Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial
Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
Predicting levodopa-induced dyskinesia
Multivariable clinical-genetic model for predicting dyskinesia in early-onset Parkinson’s disease